T1	CHEM 423 430	INS1007
T2	PROC 62 96	evaluar la eficacia y la seguridad
#1	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
T3	CHEM 103 113	medicación
#2	AnnotatorNotes T3	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T4	CHEM 126 133	INS1007
T5	DISO 179 193	bronquiectasia
#3	AnnotatorNotes T5	C0006267; Bronchiectasis; Disease or Syndrome
T6	DISO 206 223	fibrosis quística
#4	AnnotatorNotes T6	C0010674; Cystic Fibrosis; Disease or Syndrome
T7	PROC 247 340	Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, De Grupos Paralelos, Multicéntrico
T8	CHEM 1190 1205	α1-antitripsina
#5	AnnotatorNotes T8	C0002191; alpha 1-antitrypsin; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T9	PROC 347 419	Evaluar la Eficacia, la Seguridad, la Tolerabilidad y la Farmacocinética
T10	DISO 493 507	Bronquiectasia
#6	AnnotatorNotes T10	C0006267; Bronchiectasis; Disease or Syndrome
T11	DISO 520 537	Fibrosis Quística
#7	AnnotatorNotes T11	C0010674; Cystic Fibrosis; Disease or Syndrome
T12	PROC 1349 1357	tratados
#8	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	DISO 581 595	Bronquiectasia
#9	AnnotatorNotes T13	C0006267; Bronchiectasis; Disease or Syndrome
T14	DISO 608 625	fibrosis quística
#10	AnnotatorNotes T14	C0010674; Cystic Fibrosis; Disease or Syndrome
T15	PROC 992 1003	diagnóstico
#11	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 1016 1055	enfermedad pulmonar obstructiva crónica
#12	AnnotatorNotes T16	C0024117; Chronic Obstructive Airway Disease; Disease or Syndrome
T17	DISO 1058 1062	asma
#13	AnnotatorNotes T17	C0004096; Asthma; Disease or Syndrome
T18	DISO 1077 1091	bronquiectasia
#14	AnnotatorNotes T18	C0006267; Bronchiectasis; Disease or Syndrome
T19	DISO 1101 1118	fibrosis quística
#15	AnnotatorNotes T19	C0010674; Cystic Fibrosis; Disease or Syndrome
T20	DISO 1120 1141	hipogammaglobulinemia
#16	AnnotatorNotes T20	C0086438; Hypogammaglobulinemia; Disease or Syndrome
T21	DISO 1143 1175	inmunodeficiencia variable común
#17	AnnotatorNotes T21	C0009447; Common Variable Immunodeficiency; Disease or Syndrome
T22	DISO 1212 1221	fumadores
#18	AnnotatorNotes T22	C0337664; Smoker; Finding
T23	PROC 691 715	consentimiento informado
#19	AnnotatorNotes T23	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T24	DISO 1378 1396	infección pulmonar
T25	ANAT 1388 1396	pulmonar
#20	AnnotatorNotes T25	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T26	DISO 1417 1428	tuberculosa
#21	AnnotatorNotes T26	C0041296; Tuberculosis; Disease or Syndrome
T27	DISO 1430 1466	aspergilosis broncopulmonar alérgica
#22	AnnotatorNotes T27	C0004031; Aspergillosis, Allergic Bronchopulmonary; Disease or Syndrome
T28	DISO 1469 1481	tuberculosis
#23	AnnotatorNotes T28	C0041296; Tuberculosis; Disease or Syndrome
T29	PROC 797 820	índice de masa corporal
#24	AnnotatorNotes T29	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T30	ANAT 812 820	corporal
#25	AnnotatorNotes T30	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T31	ANAT 1027 1035	pulmonar
#26	AnnotatorNotes T31	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T32	DISO 1179 1205	déficit de α1-antitripsina
#27	AnnotatorNotes T32	C0221757; alpha 1-Antitrypsin Deficiency; Disease or Syndrome
T33	Date 13 17	2017
T34	Frequency 147 161	una vez al día
T35	LIVB 165 174	pacientes
#28	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Neg_cue 194 196	no
T37	PHYS 404 419	Farmacocinética
#29	AnnotatorNotes T37	C0031327; Drug Kinetics; Physiologic Function
T38	Frequency 444 458	Una Vez al Día
T39	Duration 467 477	24 Semanas
T40	LIVB 481 488	Sujetos
#30	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	Neg_cue 508 510	No
T42	Neg_cue 596 598	no
T43	LIVB 656 663	sujetos
#31	AnnotatorNotes T43	C0681850; Study Subject; Group
T44	LIVB 740 747	mujeres
#32	AnnotatorNotes T44	C0043210; Woman; Population Group
T45	Age 751 769	entre 18 y 85 años
T47	LIVB 980 987	sujetos
#33	AnnotatorNotes T47	C0681850; Study Subject; Group
T48	Duration 1048 1055	crónica
#34	AnnotatorNotes T48	C0205191; chronic; Temporal Concept
T49	Date 1358 1369	actualmente
T50	LIVB 1401 1413	micobacteria
#35	AnnotatorNotes T50	C0026907; Mycobacteriaceae; Bacterium | C0026912; Genus Mycobacterium; Bacterium
T51	Neg_cue 1414 1416	no
T52	Neg_cue 1483 1485	no
T46	LIVB 730 737	varones
#36	AnnotatorNotes T46	C0025266; Male population group; Population Group
T54	PROC 845 851	visita
#38	AnnotatorNotes T54	C1512346; Patient Visit; Health Care Activity
A1	Assertion T6 Negated
A2	Assertion T11 Negated
A3	Assertion T14 Negated
A4	Assertion T26 Negated
A5	Assertion T27 Negated
A6	Assertion T28 Negated
A7	Assertion T24 Negated
A8	Assertion T47 Negated
A9	Assertion T15 Negated
A10	Assertion T16 Negated
A11	Assertion T17 Negated
A12	Assertion T18 Negated
A13	Assertion T19 Negated
A14	Assertion T20 Negated
A15	Assertion T21 Negated
A16	Assertion T32 Negated
A17	Assertion T22 Negated
A18	Assertion T12 Negated
A19	Assertion T50 Negated
#39	AnnotatorNotes T4	C5433442; INS1007; Organic Chemical · Pharmacologic Substance
#40	AnnotatorNotes T1	C5433442; INS1007; Organic Chemical · Pharmacologic Substance
#41	AnnotatorNotes T7	C0599724; placebo controlled study; Research Activity · Intellectual Product + C2826345; Parallel Study; Research Activity + C1096776; Multicenter Study; Research Activity + C0013072; Double-Blind Method; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
#42	AnnotatorNotes T24	C0876973; Infectious Lung Disorder; Disease or Syndrome
#43	AnnotatorNotes T9	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity + C0201734; Pharmacokinetic study; Research Activity
#44	AnnotatorNotes T49	C0521116; Current (present time); Temporal Concept 
T53	Quantifier_or_Qualifier 852 853	1
T55	Observation 1492 1529	aptos para su inclusión en el estudio
A20	Assertion T55 Negated
#37	AnnotatorNotes T55	C1302261; Patient eligible for clinical trial; Finding (?)
R1	Has_Frequency Arg1:T3 Arg2:T34	
R2	Has_Frequency Arg1:T4 Arg2:T34	
R3	Experiences Arg1:T35 Arg2:T5	
R4	Negation Arg1:T36 Arg2:T6	
R5	Experiences Arg1:T35 Arg2:T6	
R6	Experiences Arg1:T35 Arg2:T3	
R7	Experiences Arg1:T35 Arg2:T4	
R8	Has_Frequency Arg1:T1 Arg2:T38	
R9	Experiences Arg1:T40 Arg2:T1	
R10	Has_Duration_or_Interval Arg1:T1 Arg2:T39	
R11	Experiences Arg1:T40 Arg2:T10	
R12	Experiences Arg1:T40 Arg2:T11	
R13	Negation Arg1:T41 Arg2:T11	
R14	Experiences Arg1:T40 Arg2:T37	
R15	Negation Arg1:T42 Arg2:T14	
R16	Has_Age Arg1:T43 Arg2:T45	
R17	Has_Age Arg1:T46 Arg2:T45	
R18	Has_Age Arg1:T44 Arg2:T45	
R19	Location_of Arg1:T30 Arg2:T29	
R20	Experiences Arg1:T43 Arg2:T29	
R21	Overlap Arg1:T29 Arg2:T54	
R22	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T53	
T56	Result_or_Value 821 827	> 18,5
R23	Has_Result_or_Value Arg1:T29 Arg2:T56	
T57	CONC 867 884	historial clínico
#45	AnnotatorNotes T57	C5204342; Clinical History; Intellectual Product
T58	Observation 911 948	aptos para su inclusión en el estudio
#46	AnnotatorNotes T58	C1302261; Patient eligible for clinical trial; Finding
R24	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T58	
R25	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T58	
R26	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T58	
T59	DISO 899 904	NCFBE
#47	AnnotatorNotes T59	C5243752; Non-cystic fibrosis bronchiectasis; Disease or Syndrome
R27	Experiences Arg1:T43 Arg2:T59	
R28	Experiences Arg1:T46 Arg2:T59	
R29	Experiences Arg1:T44 Arg2:T59	
T60	PROC 834 843	selección
#48	AnnotatorNotes T60	C0242802; Patient Selection; Research Activity
R30	Overlap Arg1:T29 Arg2:T60	
R31	Overlap Arg1:T60 Arg2:T54	
R32	Overlap Arg1:T60 Arg2:T45	
R33	Overlap Arg1:T54 Arg2:T45	
R34	Experiences Arg1:T47 Arg2:T16	
R35	Location_of Arg1:T31 Arg2:T16	
R36	Has_Duration_or_Interval Arg1:T16 Arg2:T48	
T61	Quantifier_or_Qualifier 1004 1012	primario
#49	AnnotatorNotes T61	C0205225; Primary; Qualitative Concept
R37	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T61	
R38	Negation Arg1:T52 Arg2:T55	
R39	Negation Arg1:T52 Arg2:T28	
R40	Negation Arg1:T52 Arg2:T27	
R41	Negation Arg1:T52 Arg2:T50	
R42	Negation Arg1:T51 Arg2:T26	
R43	Causes Arg1:T50 Arg2:T24	
R44	Location_of Arg1:T25 Arg2:T24	
R45	Negation Arg1:T52 Arg2:T24	
R46	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T26	
R47	Negation Arg1:T52 Arg2:T12	
R48	Overlap Arg1:T12 Arg2:T49	
R49	Negation Arg1:T52 Arg2:T22	
R50	Negation Arg1:T52 Arg2:T32	
R52	Negation Arg1:T52 Arg2:T21	
R53	Negation Arg1:T52 Arg2:T20	
R54	Negation Arg1:T52 Arg2:T19	
R55	Negation Arg1:T52 Arg2:T18	
R56	Negation Arg1:T52 Arg2:T17	
R57	Negation Arg1:T52 Arg2:T16	
R51	Experiences Arg1:T47 Arg2:T17	
R58	Experiences Arg1:T47 Arg2:T18	
R59	Experiences Arg1:T47 Arg2:T19	
R60	Experiences Arg1:T47 Arg2:T20	
R61	Experiences Arg1:T47 Arg2:T21	
R62	Experiences Arg1:T47 Arg2:T32	
R63	Experiences Arg1:T47 Arg2:T22	
R64	Experiences Arg1:T47 Arg2:T12	
R65	Experiences Arg1:T47 Arg2:T24	
R66	Experiences Arg1:T47 Arg2:T27	
R67	Experiences Arg1:T47 Arg2:T28	
R68	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T55	
R69	Experiences Arg1:T44 Arg2:T29	
R70	Experiences Arg1:T46 Arg2:T29	
R71	Experiences Arg1:T46 Arg2:T54	
R72	Experiences Arg1:T44 Arg2:T54	
#50	AnnotatorNotes T53	C0205447; One; Quantitative Concept
A21	Experiencer T35 Patient
A22	Experiencer T40 Patient
A23	Experiencer T43 Patient
A24	Experiencer T46 Patient
A25	Experiencer T44 Patient
A26	Experiencer T47 Patient
A27	Status T55 Future
A28	Status T58 Future
